← Human Trials & Peer-Reviewed Studies
Carnosine supplementation improves cognitive outcomes in younger participants of the NEAT trial
Plain-language guide to PMID 39919936 (2025): double-blind randomized controlled trial study of Carnosine in 299 participants.
Key Facts
- PMID
- 39919936
- Journal
- Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- O'Toole TE et al. (7 authors)
- DOI
- 10.1016/j.neurot.2025.e00541
What This Study Did, in Plain Language
What Was Tested
Researchers studied Carnosine in this randomized controlled trial publication.
The researchers examined this as a post-hoc secondary outcome in the placebo-controlled, randomized Nucleophilic Defense Against PM Toxicity (NEAT) clinical trial (NCT03314987).
Speed, accuracy, and efficiency were obtained for the whole battery as well as for each of the ten individual tests.
Who Took Part
According to the abstract, 299 participants were involved.
The age groups tagged for this paper are young adults, adults and middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Carnosine and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received Carnosine.
The comparison arm used a placebo, so changes seen with Carnosine could be set against what happens without it.
Cognitive ability was assessed using the Cognition test battery, which consists of ten individual tests known to engage specific brain systems and covering a range of cognitive domains.
What Was Measured
The researchers examined this as a post-hoc secondary outcome in the placebo-controlled, randomized Nucleophilic Defense Against PM Toxicity (NEAT) clinical trial (NCT03314987).
Speed, accuracy, and efficiency were obtained for the whole battery as well as for each of the ten individual tests.
Topics PubMed links to this paper include Carnosine, Dietary Supplements, Cognition and Neuropsychological Tests.
Author keywords: Clinical trial.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Carnosine in 299 participants.
The publication is from 2025 (Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics), a journal based in United States.
More context: the Carnosine compound page, all human trials.
Our Notes on the Compound
Carnosine: A dipeptide of beta-alanine and histidine found in muscle and brain; studied as a supplement in human trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.